Combining Value, Growth and Momentum
10x Stocks - Searching for multibaggers
  • Blog
  • Performance
  • Investment strategy
  • About

Small cap watch (BLUE)

6/17/2014

0 Comments

 
Picture
Bluebird bio is a biotechnology company developing next generation products based on gene therapy to treat patients with severe genetic and orphan diseases. They have two clinical stage products in development for childhood cerebral adrenoleukodystrophy and beta-thalassemia/sickle cell disease, a preclinical oncology program in partnership with Celgene.

The company broke news on Saturday, when it announced that Two patients with a serious, inherited blood disorder have been able to stop blood transfusions following a single treatment with an experimental gene therapy developed by BLUE. The patients reported have beta-thalassemia (B-thal), a disease caused by a missing or defective gene which prevents oxygen-carrying hemoglobin from functioning properly. The Bluebird therapy, also called LentiGlobin, replaces the defective gene with a functional one.

"Following the (gene) transplant, we're seeing near normal levels of hemoglobin. These early results far exceeded our expectations," said Chief Medical Officer David Davidson. 

The company estimates, that there are about 15,000 patients with B-thal in the U.S. and Europe, and 270 000 in other parts of the world, with 60 000 new cases each year. In addition, they therapy has also many other uses, which might be the reason Celgene (CELG) is partnering with them (10-K):

"We believe that our vectors can be used to introduce virtually any gene into a cell and have the potential to be manufactured on a commercial scale reproducibly and reliably, as each new vector is produced using substantially the same process."

The stock shot up 32%, reaching a new all-time high and a market cap of $844 million. It hasn't been bought by insiders since it's IPO. The total float is 22 million while 5.7% of that is short. The company has currently 192 million in cash, which they believe will be enough until at least the end of 2015.
0 Comments



Leave a Reply.

    To make money in stocks you must have the "the vision to see them, the courage to buy them and the patience to hold them". And patience is the rarest of the three.  Thomas Phelps

    Follow @BestStocksNow

    Categories

    All
    Best Stocks Of 2013
    Best Stocks Of 2014
    HK Stocks
    Indian Stocks
    Long
    Uk Stocks
    US Stocks

    Archives

    April 2021
    January 2021
    September 2020
    August 2020
    May 2020
    August 2019
    July 2019
    June 2019
    February 2019
    May 2018
    August 2017
    July 2016
    February 2016
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    September 2014
    August 2014
    July 2014
    June 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013

    RSS Feed

Powered by Create your own unique website with customizable templates.